Smooth Muscle Neoplasm
Associated Genetic Biomarkers
NCI Definition: A benign or malignant myomatous neoplasm arising from smooth muscle. 
Smooth muscle neoplasms most frequently harbor alterations in TP53, RB1, ATRX, MED12, and PTEN .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, RB1 Loss, and ATRX Mutation are the most common alterations in smooth muscle neoplasm .
There is 1 clinical trial for smooth muscle neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains smooth muscle neoplasm as an inclusion criterion, 1 is phase 1 (1 open).
EBV is the most frequent gene inclusion criterion for smooth muscle neoplasm clinical trials .
Mabel ctls, cyclophosphamide, and fludarabine are the most common interventions in smooth muscle neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.